ArticleInternational journal of clinical and experimental medicine2015
(18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.International journal of clinical oncology · 2021Article
- A Formula to Calculate the Threshold for Radiotherapy Targets on PET Images: Simulation Study.Frontiers in oncology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate whether during/post-radiotherapy FDG uptake locations within tumors is likely identified using a pre-radiotherapy scan for non-small cell lung cancer (NSCLC), ultimately enabling confirm that a suitable metabolically active sub-volume pre-radiotherapy of the primary tumor for radiation boosting target.
methodsPatients with a pathologically proven inoperable stage II-III NSCLC were enrolled. For each patient, one pre-radiotherapy (pre-RT) plus one following 40Gy during-radiotherapy (during-RT) or post-radiotherapy (post-RT) FDG PET/CT scans were available. On pre-RT scan, the high FDG uptake region were auto-delineated using several percentage of the maximal standardized uptake value (SUVmax) thresholds, varying from 40% to 70%. On during-RT scan, FDG uptake region is delineated by 40% SUVmax, manual method respectively. With the FDG-positive areas on post-RT images is defined as 80% SUVmax. The overlap fractions (OFs) were calculated between pre-RT scan and during-RT or post-RT scan. Semi-quantitative assessment was used to determine SUVmax and metabolic tumor volume (MTV). The SUVmax changes during-RT representing the radiotherapy (RT) early metabolic response is attainable. Then, a spearman correlation was used to analysis the correlation between percentage changes in SUVmax during-RT and SUVmax-threshold definition volume pre-RT.
resultsOf those 7 patients, a total of 16 FDG-PET scans were acquired. 5 patients were received pre-RT and during-RT scan, while 2 of these 5 patients underwent both post-RT scan. 2 patients were received FDG-PET/CT scan pre-RT and post-RT. The pre-RT scan threshold delineations of 50% SUVmax had a large OF with the 40% SUVmax threshold and manual method delineation on the during-RT scan, 74.3% and 84.4%, respectively. Comparably, the 80% SUVmax on the post-RT scan also largely corresponded (OF > 72%) with the 50% SUVmax threshold and the volume was small compared to the gross tumor volume (GTV), accounting for 29.4%. However, the 50% SUVmax threshold was not correlate with the percentage change in SUVmax (P > 0.05).
conclusionsA pre-RT FDG-PET scan allows for the identification of during- and post-RT FDG uptake locations. The volume defined by 50% SUVmax may be a suitable threshold for dose escalation.
Indexed as
Identifiers
26221300PMC4509245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.